

Table 1. Sensitivity analysis – cost-effectiveness of placebo vs. trial intervention

	Placebo (n=48)	DNase (n=41)	t-PA (n=44)	t-PA-DNase (n=45)
Total costs €, mean (S.D.)				
Weighted- average cost for readmissions	13,836 (29,236)	17,355 (34,162)	10,657 (15,527)	7,261 (4,952)
50% reduction in trial medication costs	13,483 (28,798)	17,737 (34,849)	10,109 (14,408)	6,639 (4,920)
100% increase in trial medication costs	13,483 (28,798)	18,076 (34,849)	11,587 (15,408)	8,457 (4,920)
Life-years gained, mean (S.D.)				
Life-years	0.969 (0.147)	0.923 (0.228)	0.988 (0.081)	0.969 (0.153)
Cost-effectiveness – placebo vs. trial intervention (ICER)				
Weighted- average cost for readmissions	N/A	Placebo dominant	t-PA dominant	€1.7 billion
50% reduction in trial medication costs	N/A	Placebo dominant	t-PA dominant	€1.8 billion
100% increase in trial medication costs	N/A	Placebo dominant	t-PA dominant	€1.3 billion